Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin

by Giovannetti, E, Zucali, P A, Assaraf, Y G, Leon, L G, Smid, K, Alecci, C, Giancola, F, Destro, A, Gianoncelli, L, Lorenzi, E, Roncalli, M, Santoro, A, Peters, G J
Published 2011

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours

by Zucali, P A, Simonelli, M, De Vincenzo, F, Lorenzi, E, Perrino, M, Bertossi, M, Finotto, R, Naimo, S, Balzarini, L, Bonifacio, C, Timofeeva, I, Rossoni, G, Mazzola, G, Lambiase, A, Bordignon, C, Santoro, A
Published 2013

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

by Ceresoli, G L, Zucali, P A, Mencoboni, M, Botta, M, Grossi, F, Cortinovis, D, Zilembo, N, Ripa, C, Tiseo, M, Favaretto, A G, Soto-Parra, H, De Vincenzo, F, Bruzzone, A, Lorenzi, E, Gianoncelli, L, Ercoli, B, Giordano, L, Santoro, A
Published 2013